Is CMVLF or JEPQ a better dividend investment in 2026?

CMVLF currently yields 64.94% with a 5% 5-year dividend growth rate. JEPQ yields 11.10% with 5% growth. The better choice depends on your goal: CMVLF offers higher current income.

What is the dividend yield difference between CMVLF and JEPQ?

CMVLF has a forward dividend yield of 64.94% ($2.00/share annually). JEPQ yields 11.10% ($6.16/share annually). The yield gap is 53.84 percentage points.

Home › Compare › CMVLF vs JEPQ

CMVLF vs JEPQ: Dividend Comparison 2026

CMVLF yields 64.94% · JEPQ yields 11.10%● Live data

vsPost on X →

After 10 years · $10,000 invested · DRIP enabled

🏆 CMVLF wins by $782.7K in total portfolio value

INVESTMENT

TIME HORIZON10 years

CMVLF

● Live price

64.94%

Share price

$3.08

Annual div

$2.00

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$827.5K

Annual income

$205,354.23

Full CMVLF calculator →

JEPQ

JPMorgan Nasdaq Equity Premium Income ETF

● Live price

11.10%

Share price

$55.52

Annual div

$6.16

5Y div CAGR

Payout ratio

50%

After 10 yrs · $10,000 · DRIP

Portfolio value

$44.8K

Annual income

$2,152.59

Full JEPQ calculator →

Portfolio growth — CMVLF vs JEPQ

📍 CMVLF pulled ahead of the other in Year 1

Annual dividend income

🛡️

Recession Test — Did They Cut Dividends?

How each stock treated shareholders during the 3 biggest crises of the last 20 years

Crisis Period	CMVLF	JEPQ
2008–2009 GFC	— No data	— No data
2020 Q1–Q2 COVID	— No data	— No data
2022 Q4 Rate Hike	— No data	— No data

Based on dividend payment history. "Increased" = dividend grew during crisis. "Maintained" = held within 3%. "Cut" = reduced by more than 3%.

📅

Dividend Calendar Overlap

Combined, CMVLF + JEPQ cover 0 of 12 months — good coverage

Jan

—

Feb

—

Mar

—

Apr

—

May

—

Jun

—

Jul

—

Aug

—

Sep

—

Oct

—

Nov

—

Dec

—

CMVLF pays

JEPQ pays

Both pay

Neither

💰

Tax Bracket Optimizer

Which stock is actually better after tax? Adjust your rate to find out.

CMVLF

Annual income on $10K today (after 15% tax)

$5,519.48/yr

After 10yr DRIP, annual income (after tax)

$174,551.10/yr

JEPQ

Annual income on $10K today (after 15% tax)

$943.83/yr

After 10yr DRIP, annual income (after tax)

$1,829.70/yr

At 15% tax rate, CMVLF beats the other by $172,721.39/year in after-tax income after 10 years on $10,000

⚖️

Lazy Portfolio Split Optimizer

What's the optimal mix of CMVLF + JEPQ for your $10,000?

CMVLF: 50%JEPQ: 50%

100% JEPQ50/50100% CMVLF

Portfolio after 10yr

$436.1K

Annual income

$103,753.41/yr

Blended yield

23.79%

📊

Analyst Conviction Gap

Where Wall Street is most bullish on CMVLF right now

CMVLF

Analyst Ratings

Buy

Hold

Sell

Consensus: Buy

Altman Z

-0.9

Piotroski

2/9

JEPQ

No analyst data

Analyst ratings via FMP. Altman Z-Score: >3.0 safe, 1.81–3.0 grey zone, <1.81 distress. Piotroski: 7–9 strong, 0–3 weak.

🏛️

Copy Congress — What Are Politicians Buying?

Senate & House STOCK Act disclosures (last 90 days)

CMVLF buys

JEPQ buys

No recent congressional trades found for CMVLF or JEPQ in the last 90 days.

STOCK Act mandates disclosure within 45 days of transaction. Data via FMP.Full tracker →

MetricCMVLFJEPQ

Forward yield	64.94% ✓	11.10%
Annual dividend / share	$2.00	$6.16 ✓
Payout ratio	50%	50%
1-year div growth	0%	0%
5-year div CAGR	0%	0%
Portfolio after 10y	$827.5K ✓	$44.8K
Annual income after 10y	$205,354.23 ✓	$2,152.59
Total dividends collected	$696.1K ✓	$16.3K
Payment frequency	quarterly	monthly
Sector	Stock	ETF

Year-by-year: CMVLF vs JEPQ ($10,000, DRIP)

Year	CMVLF Portfolio	CMVLF Income/yr	JEPQ Portfolio	JEPQ Income/yr	Gap
1← crossover	$17,194	$6,493.51	$11,930	$1,110.39	+$5.3K → CMVLF
2	$28,831	$10,434.22	$14,133	$1,224.34	+$14.7K → CMVLF
3	$47,202	$16,352.17	$16,632	$1,340.46	+$30.6K → CMVLF
4	$75,526	$25,019.87	$19,454	$1,457.97	+$56.1K → CMVLF
5	$118,227	$37,414.37	$22,626	$1,576.08	+$95.6K → CMVLF
6	$181,239	$54,736.40	$26,175	$1,694.09	+$155.1K → CMVLF
7	$272,346	$78,420.28	$30,133	$1,811.32	+$242.2K → CMVLF
8	$401,542	$110,132.11	$34,531	$1,927.17	+$367.0K → CMVLF
9	$581,404	$151,754.11	$39,403	$2,041.08	+$542.0K → CMVLF
10	$827,457	$205,354.23	$44,787	$2,152.59	+$782.7K → CMVLF

CMVLF vs JEPQ: Complete Analysis 2026

CMVLF — Stock

Cellectis S.A., a clinical stage biotechnological company, develops immuno-oncology products based on gene-edited T-cells that express chimeric antigen receptors to target and eradicate cancer cells. It operates through two segments, Therapeutics and Plants. The company is developing UCART19, an allogeneic T-cell product candidate for the treatment of CD19-expressing hematologic malignancies, such as acute lymphoblastic leukemia; ALLO-501 and ALLO-501A to treat relapsed/refractory diffuse large B-cell lymphoma and follicular lymphoma; ALLO-316 for the treatment of Renal Cell Carcinoma; UCART123 for the treatment of acute myeloid leukemia; and UCART22 to treat B-cell acute lymphoblastic leukemia. It is also developing UCARTCS1 and ALLO-715 for the treatment of multiple myeloma. The company has strategic alliances with Allogene Therapeutics, Inc.; Les Laboratoires Servier; The University of Texas M.D. Anderson Cancer Center; and Iovance Biotherapeutics, as well as a strategic research and development collaboration with Cytovia Therapeutics, Inc. Cellectis S.A. was founded in 1999 and is headquartered in Paris, France.

Full CMVLF Calculator →

JEPQ — ETF

The fund seeks to achieve this objective by (1) creating an actively managed portfolio of equity securities comprised significantly of those included in the fund’s primary benchmark, the Nasdaq-100 Index (the Benchmark), and (2) through equity-linked notes (ELNs), selling call options with exposure to the Benchmark. It is non-diversified.

Full JEPQ Calculator →

📬

Get this CMVLF vs JEPQ comparison by email

Save your analysis + weekly dividend insights. Free forever.

More comparisons

CMVLF vs SCHD CMVLF vs JEPI CMVLF vs O CMVLF vs KO CMVLF vs MAIN CMVLF vs XYLD CMVLF vs QYLD CMVLF vs VYM

⚠️ Educational purposes only. Not financial advice. Congressional trades sourced from SEC STOCK Act filings via FMP. Past performance does not guarantee future results.